When combined with knockdown of another kinase like EDN2, TBK1 silencing further amplifies paclitaxel sensitivity, increasing apoptosis and cell-cycle arrest, thereby improving paclitaxel effectiveness in ovarian cancer treatment (77). The gene discussed is TBK1; the disease is ovarian carcinoma.